Join our daily newsletter At The Bell to receive exclusive market insights
- Immuron’s (IMC) travellers diarrhoea preventative medication Travelan is set to be tested for efficacy to inform strategies for defence force health protection
- The study is being conducted by the US Department of Defense Uniformed Services University (USU), alongside the UK Ministry of Defense and the New York Travel Clinic
- Travelan will be tested alongside two other over the counter preventative medications in a double-blind, placebo-controlled study in 1336 people traveling to high-TD risk regions
- USU expects to begin recruiting for the study in in June
- Shares in IMC have gone up 4.76 per cent today, trading at 11 cents at market close
A new trial is set to begin to test Immuron’s (IMC) preventative travellers diarrhoea medication, Travelan, to evaluate its effectiveness which will inform strategies for Defence Force Health Protection.
The study is being jointly conducted by the US Department of Defense Uniformed Services University’s (USU) Infectious Diseases Clinical Research Program, alongside the UK Ministry of Defense and the New York City Travel Clinic.
In the P4TD randomised, double-blind, placebo-controlled study, three over the counter nutraceutical products that treat traveller’s diarrhoea (TD) will be tested alongside a placebo, to see how effective they are in preventing the disease.
Those three products include Bimuno – a prebiotic, Florastor – a probiotic, and Immuron’s Travelan.
The study will involve 1336 participants traveling to high-TD risk regions, who will all be randomly assigned one of the three active products or a placebo, with 334 people assigned to each arm.
The company says USU has completed the manufacture of the first batches of investigational medicinal products and has shipped these to the first clinical trial sites.
USU expect to begin recruiting participants for the study in June this year, with clinical trial enrolment in approximately 18 months.
In addition, the clinical protocol has been amended to extend the treatment period from 13 to 22 days, in order to cover the COVID-19 quarantine period still required in some countries.
The company says this is because travellers in quarantine could still be at risk of catching TD during this period. The protocol amendment has been submitted to the ethics board for approval, and recruitment will commence once this has been granted.
Shares in IMC went up 4.76 per cent today, trading at 11 cents at market close.
